Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630355 | 0.84 | IRAK4 (0.41) | CSF1R | |
| SCHEMBL4911450 | 0.80 | PARP1 (0.43) | IKBKBCLK4HPGDS | |
| SCHEMBL3085799 | 0.80 | MAP4K4 (0.41) | IKBKBMAOBBRD4 | |
| SCHEMBL3659396 | 0.77 | CYP11B2 (0.49) | SLC22A12 | |
| SCHEMBL3660537 | 0.77 | CNR2 (0.43) | CDC7XDHPTGDR2 | |
| SCHEMBL2636302 | 0.77 | BCAT2 (0.53) | IKBKBCHUK | |
| SCHEMBL20703692 | 0.77 | BCAT2 (0.59) | IKBKBCHUKADRA2CCDC7SLC22A12 | |
| SCHEMBL7117229 | 0.75 | IKBKB (0.51) | IKBKBCHUKBRD4 | |
| SCHEMBL3091864 | 0.75 | PARP1 (0.49) | IKBKBCDC7 | |
| SCHEMBL5144593 | 0.75 | CLK4 (0.47) | ADRA2CSLC22A12XDHPTGDR2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| US-7790712-B2 | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | IKBKB 162/4885CHUK 82/4885ADRA2C 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.